Generic placeholder image

Current Clinical Pharmacology

Editor-in-Chief

ISSN (Print): 1574-8847
ISSN (Online): 2212-3938

Vanadium Complexes with Hydrazone or Thiosemicarbazone Ligands as Potential Anti-Mycobacterium tuberculosis Agents

Author(s): Paula C. de Souza, Pedro I. S. Maia, Heloisa B. de Barros, Clarice Q. F. Leite, Victor M. Deflon and Fernando R. Pavan

Volume 10 , Issue 1 , 2015

Page: [66 - 72] Pages: 7

DOI: 10.2174/1574884708666131229124748

Price: $65

Abstract

Tuberculosis (TB) is an infectious disease caused mainly by Mycobacterium tuberculosis (MTB) and still an important public health problem worldwide. Some factors like the emergence of multidrug resistant (MDR) and extensively drug-resistant (XDR) strains make urgent the research of new active compounds. Searching for new inorganic compounds against TB, three new dioxovanadium(V) complexes were obtained upon reaction of [VO(acac)2] with hydrazone and thiosemicarbazone ligands derived from di-2-pyridyl ketone. Spectroscopic studies and X-ray crystallography revealed asymmetrically oxo bridged binuclear complexes of the type [{VO(L1,2)}2(μ-O)2], involving the hydrazone ligands, while a mononuclear square pyramidal complex of the type [VO2(L3)] was formed with the thiosemicarbazone ligand. The compounds were tested against M. tuberculosis and three of them, with MICs values between 2.00 and 3.76 μM were considered promising for TB treatment. Such MIC values are comparable or better than those found for some drugs currently used in TB treatment.

Keywords: Dioxovanadium(V), hydrazone, Mycobacterium tuberculosis, new antituberculosis compounds, thiosemicarbazone.


Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy